Cwm LLC Has $3.78 Million Position in Boston Scientific Corporation (NYSE:BSX)

CWM LLC raised its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 8.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,476 shares of the medical equipment provider's stock after buying an additional 2,844 shares during the period. CWM LLC's holdings in Boston Scientific were worth $3,781,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of BSX. Colonial Trust Co SC increased its holdings in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 260 shares in the last quarter. Investment Management Corp VA ADV bought a new position in shares of Boston Scientific in the fourth quarter valued at $25,000. Sunbeam Capital Management LLC bought a new position in shares of Boston Scientific in the fourth quarter valued at $26,000. Ameriflex Group Inc. bought a new position in shares of Boston Scientific in the fourth quarter valued at $31,000. Finally, Fourth Dimension Wealth LLC bought a new position in shares of Boston Scientific in the fourth quarter valued at $36,000. Institutional investors own 89.07% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on BSX. Wall Street Zen raised Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. BTIG Research reiterated a "buy" rating and set a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, April 23rd. Truist Financial lifted their price objective on shares of Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a research report on Thursday, April 24th. Evercore ISI lifted their price objective on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $115.00 price objective on shares of Boston Scientific in a research report on Wednesday, May 28th. Twenty-two equities research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $116.09.

Boston Scientific Stock Down 0.9%

NYSE:BSX traded down $0.97 during trading hours on Friday, reaching $103.68. The company's stock had a trading volume of 8,571,006 shares, compared to its average volume of 6,770,436. The company has a market cap of $153.39 billion, a price-to-earnings ratio of 75.68, a price-to-earnings-growth ratio of 2.68 and a beta of 0.68. Boston Scientific Corporation has a one year low of $71.88 and a one year high of $107.53. The business's 50-day moving average is $103.40 and its 200-day moving average is $100.90. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The firm had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. Boston Scientific's revenue for the quarter was up 20.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.56 earnings per share. Equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the transaction, the senior vice president owned 36,193 shares of the company's stock, valued at $3,441,592.37. The trade was a 11.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $106.97, for a total transaction of $5,348,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at approximately $19,077,243.74. This represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 461,970 shares of company stock valued at $47,755,193 in the last three months. 0.50% of the stock is currently owned by company insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.